Ervebois is indicated for active immunisation of the paediatric population against Zaire ebolavirus-caused Ebola virus disease. Credit: Novikov Aleksey / Shutterstock.com.
ReportsLOA and PTSR Model - meningococcal [serotype A, C, W-135, X and Y] vaccine GlobalData
ReportsLOA and PTSR Model - Genital Herpes Vaccine in Genital Herpes GlobalData
The live recombinant viral vaccine comprises a vesicular stomatitis virus (VSV) backbone with the VSV envelope glycoprotein removed and replaced with the Zaire ebolavirus’s (Kikwit 1995 strain) envelope glycoprotein.
The vaccine is currently approved in the European Union for active immunisation in those aged 18 years or above.
Merck Research Laboratories global clinical development senior vice-president and chief medical officer Dr Eliav Barr stated: “The European Commission’s expanded approval of Ervebo for children one year of age and older is an important milestone for the prevention of disease caused by Zaire ebolavirus.
“When outbreaks of Ebola virus disease occur, they can quickly become a public health crisEuropean Medicines Agencya role, alongside the global public health community, in helping to prepare for potential outbreaks of Zaire ebolavirus.” The US Food and Drug Administration approved the expanded indication of Ervebo for usage in children aged 12 months and above in August 2023.
Merck Research Laboratoriesg and response activities for future outbreaks, the company signed an agreement with the United Nations International Children’s Emergency Fund in Erveboy 2021, under which a global Ebola vaccine stockpile is being created using Ervebo.